Charles McWherter
Nessuna posizione attualmente
Profilo
Charles A.
McWherter worked as the VP & Head-Cardiovascular Therapeutics Areas at Pfizer Inc. from 2003 to 2007.
Prior to that, he served as the Vice President-Drug Discovery at Sugen, Inc. from 2001 to 2003.
Currently, he is the President-Research & Development at CymaBay Therapeutics, Inc. since 2022.
Dr. McWherter holds a doctorate degree from Cornell University.
Precedenti posizioni note di Charles McWherter
| Società | Posizione | Fine |
|---|---|---|
| CYMABAY THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 22/03/2024 |
| PFIZER, INC. | Corporate Officer/Principal | 01/01/2007 |
Sugen, Inc.
 Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2003 |
Formazione di Charles McWherter
| Cornell University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Sugen, Inc.
Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
- Borsa valori
- Insiders
- Charles McWherter
